{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:34:00Z","timestamp":1789842840566,"version":"4.0.1"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,25]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare necrotising vasculitis affecting small vessels accompanied by eosinophilic inflammation. Biological therapies, particularly anti-interleukin-5 (IL-5) monoclonal antibodies, have been shown to be effective in treating refractory EGPA. Mepolizumab, an anti-IL-5 monoclonal antibody, has been approved in Japan for the treatment of EGPA and has a significant glucocorticoid-sparing effect. Benralizumab, an anti-IL-5 receptor monoclonal antibody, has also been reported to reduce the glucocorticoid dose in patients with EGPA. However, several investigators have reported the development of EGPA during biologic treatment. Herein, we present a case of development of refractory EGPA under benralizumab treatment. Although the initial treatment with high-dose glucocorticoids and the administration of benralizumab were temporally effective, the patient\u2019s condition did not improve, and the eosinophil count reelevated. After switching benralizumab to mepolizumab, the patient\u2019s condition improved, and remission was achieved. Our report suggested that mepolizumab may be an effective treatment option for refractory EGPA after failure of benralizumab treatment.<\/jats:p>","DOI":"10.1093\/mrcr\/rxaf008","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T23:25:57Z","timestamp":1737761157000},"source":"Crossref","is-referenced-by-count":7,"title":["Successful switching treatment of mepolizumab for refractory eosinophilic granulomatosis with polyangiitis and multiple organ dysfunction under benralizumab treatment: A case report"],"prefix":"10.1093","volume":"9","author":[{"given":"Toshitaka","family":"Yukishima","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Seirei Hamamatsu General Hospital , Hamamatsu, Shizuoka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Yonezawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Seirei Hamamatsu General Hospital , Hamamatsu, Shizuoka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Aono","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Seirei Hamamatsu General Hospital , Hamamatsu, Shizuoka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Seirei Hamamatsu General Hospital , Hamamatsu, Shizuoka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiro","family":"Otsuki","sequence":"additional","affiliation":[{"name":"Department of Pathology, Seirei Hamamatsu General Hospital , Hamamatsu, Shizuoka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8651-4149","authenticated-orcid":false,"given":"Shin-ichiro","family":"Ohmura","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Seirei Hamamatsu General Hospital , Hamamatsu, Shizuoka,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,25]]},"reference":[{"key":"2025080201021808400_R1","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/art.41534","article-title":"Use of biologics to treat relapsing and\/or refractory eosinophilic granulomatosis with polyangiitis: data from a European collaborative study","volume":"73","author":"Canzian","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025080201021808400_R2","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"2025080201021808400_R3","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.jaip.2020.09.054","article-title":"Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis","volume":"9","author":"Guntur","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025080201021808400_R4","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa2311155","article-title":"Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis","volume":"390","author":"Wechsler","year":"2024","journal-title":"N Engl J Med"},{"key":"2025080201021808400_R5","doi-asserted-by":"crossref","first-page":"165","DOI":"10.18176\/jiaci.0823","article-title":"Eosinophilia induced by blocking the il-4\/il-13 pathway: potential mechanisms and clinical outcomes","volume":"32","author":"Olaguibel","year":"2022","journal-title":"J Investig Allergol Clin Immunol"},{"key":"2025080201021808400_R6","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1016\/j.jaip.2020.04.006","article-title":"Eosinophilic granulomatosis with polyangiitis evolution during severe eosinophilic asthma treatment with benralizumab","volume":"8","author":"Hocevar","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2025080201021808400_R7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/mrcr\/rxad028","article-title":"New-onset of eosinophilic granulomatosis with polyangiitis without eosinophilia and eosinophilic infiltration under benralizumab treatment: a case report","volume":"8","author":"Yonezawa","year":"2023","journal-title":"Mod Rheumatol Case Rep"},{"key":"2025080201021808400_R8","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/art.41982","article-title":"2022 American College of Rheumatology\/European Alliance of Associations for rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis","volume":"74","author":"Grayson","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2025080201021808400_R9","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1136\/ard.2008.101279","article-title":"Modification and validation of the Birmingham vasculitis activity score (version 3)","volume":"68","author":"Mukhtyar","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2025080201021808400_R10","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2025080201021808400_R11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1146\/annurev.immunol.24.021605.090720","article-title":"The eosinophil","volume":"24","author":"Rothenberg","year":"2006","journal-title":"Annu Rev Immunol"},{"key":"2025080201021808400_R12","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.crimmu.2022.03.002","article-title":"The emerging roles of eosinophils: implications for the targeted treatment of eosinophilic-associated inflammatory conditions","volume":"3","author":"Lombardi","year":"2022","journal-title":"Curr Res Immunol"},{"key":"2025080201021808400_R13","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/stem.140605","article-title":"Function and signal transduction mediated by the interleukin 3 receptor system in hematopoiesis","volume":"14","author":"Hara","year":"1996","journal-title":"Stem Cells"},{"key":"2025080201021808400_R14","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1111\/all.14620","article-title":"Adult-onset eosinophilic airway diseases","volume":"75","author":"Asano","year":"2020","journal-title":"Allergy"},{"key":"2025080201021808400_R15","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/all.14221","article-title":"Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI guidelines - recommendations on the use of biologicals in severe asthma","volume":"75","author":"Agache","year":"2020","journal-title":"Allergy"},{"key":"2025080201021808400_R16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1204444","article-title":"Effectiveness and safety of anti-IL-5\/Ralpha biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study","volume":"14","author":"Nolasco","year":"2023","journal-title":"Front Immunol"},{"key":"2025080201021808400_R17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/gut.2009.178558","article-title":"Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial","volume":"59","author":"Straumann","year":"2010","journal-title":"Gut"},{"key":"2025080201021808400_R18","doi-asserted-by":"crossref","first-page":"84","DOI":"10.18176\/jiaci.0385","article-title":"Benralizumab: a new approach for the treatment of severe eosinophilic asthma","volume":"29","author":"Davila Gonzalez","year":"2019","journal-title":"J Investig Allergol Clin Immunol"},{"key":"2025080201021808400_R19","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000478077","article-title":"The immunogenicity of biologic therapies","volume":"53","author":"Garces","year":"2018","journal-title":"Curr Probl Dermatol"},{"key":"2025080201021808400_R20","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"key":"2025080201021808400_R21","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"key":"2025080201021808400_R22","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"2025080201021808400_R23","doi-asserted-by":"crossref","DOI":"10.1208\/s12248-018-0207-8","article-title":"Selection of a ligand-binding neutralizing antibody assay for benralizumab: comparison with an antibody-dependent cell-mediated cytotoxicity (ADCC) cell-based assay","volume":"20","author":"Wu","year":"2018","journal-title":"AAPS J"},{"key":"2025080201021808400_R24","doi-asserted-by":"crossref","DOI":"10.1002\/rcr2.1431","article-title":"Eosinophilic granulomatosis with polyangiitis developed during treatment with benralizmab for severe asthma: a case report and literature review","volume":"12","author":"Sakabe","year":"2024","journal-title":"Respirol Case Rep"},{"key":"2025080201021808400_R25","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1093\/rheumatology\/keaa572","article-title":"Onset of eosinophilic granulomatosis with polyangiitis in a patient treated with an IL-5 pathway inhibitor for severe asthma","volume":"60","author":"Caminati","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2025080201021808400_R26","article-title":"Emergence of extrathoracic manifestations of eosinophilic granulomatosis with polyangiitis during benralizumab treatment","volume":"5","author":"Lim","year":"2021","journal-title":"Rheumatol Adv Pract"},{"key":"2025080201021808400_R27","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.alit.2022.08.004","article-title":"Development of vasculitis in a case with severe asthma treated with benralizumab and low-dose corticosteroid","volume":"72","author":"Umezawa","year":"2023","journal-title":"Allergol Int"},{"key":"2025080201021808400_R28","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s12026-022-09317-5","article-title":"New-onset eosinophilic granulomatosis with polyangiitis in 2 patients during treatment with IL-5 pathway inhibitors","volume":"70","author":"Holubar","year":"2022","journal-title":"Immunol Res"},{"key":"2025080201021808400_R29","article-title":"Eosinophilic granulomatosis with polyangiitis resembling Guillain-Barre syndrome under benralizumab treatment","volume":"8","author":"Wakatsuki","year":"2024","journal-title":"Rheumatol Adv Pract"},{"key":"2025080201021808400_R30","doi-asserted-by":"crossref","DOI":"10.4081\/mrm.2021.779","article-title":"Successful treatment with benralizumab in a patient with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab","volume":"16","author":"Menzella","year":"2021","journal-title":"Multidiscip Respir Med"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxaf008\/61623111\/rxaf008.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/2\/rxaf008\/61623111\/rxaf008.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/2\/rxaf008\/61623111\/rxaf008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T05:02:39Z","timestamp":1754110959000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/doi\/10.1093\/mrcr\/rxaf008\/7979024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,7,25]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxaf008","relation":{},"ISSN":["2472-5625"],"issn-type":[{"value":"2472-5625","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2025]]},"article-number":"rxaf008"}}